MORABITO, FABIO
 Distribuzione geografica
Continente #
NA - Nord America 158
EU - Europa 67
AS - Asia 52
SA - Sud America 17
AF - Africa 7
Totale 301
Nazione #
US - Stati Uniti d'America 155
SG - Singapore 43
IT - Italia 26
BR - Brasile 17
IE - Irlanda 16
FI - Finlandia 8
CI - Costa d'Avorio 7
DE - Germania 5
CN - Cina 4
CZ - Repubblica Ceca 4
CA - Canada 2
NL - Olanda 2
RU - Federazione Russa 2
SA - Arabia Saudita 2
AT - Austria 1
CH - Svizzera 1
FR - Francia 1
IN - India 1
KZ - Kazakistan 1
MX - Messico 1
UA - Ucraina 1
UZ - Uzbekistan 1
Totale 301
Città #
Santa Clara 59
Singapore 34
Chicago 23
Dublin 16
Civitanova Marche 13
Chandler 11
Boardman 8
Turku 8
Abidjan 7
Andover 4
Cambridge 4
Lawrence 4
Munich 4
Ashburn 3
Catania 3
Des Moines 3
Montreal 2
Scarsdale 2
Arroio Grande 1
Beijing 1
Belem 1
Belo Horizonte 1
Bernareggio 1
Blumenau 1
Boston 1
Brandywine 1
Campinas 1
Chennai 1
Cranston 1
Curitiba 1
Dallas 1
Dammam 1
Guaratinguetá 1
Guarulhos 1
Gustavo Adolfo Madero 1
Itajuípe 1
Itapetinga 1
Jeddah 1
Jequié 1
João Pessoa 1
Los Angeles 1
Mauá 1
Milan 1
New York 1
Olomouc 1
Phoenix 1
Redmond 1
Redwood City 1
Rome 1
Santa Maria 1
Santaluz 1
Seattle 1
Sete Lagoas 1
Shymkent 1
Veranópolis 1
Wilmington 1
Totale 246
Nome #
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 56
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia 52
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 49
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 46
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment 31
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial 27
Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases 26
In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia 24
Totale 311
Categoria #
all - tutte 1.350
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.350


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202113 0 0 0 0 0 0 10 0 3 0 0 0
2021/202220 0 4 0 0 4 0 4 0 1 0 0 7
2022/202338 4 3 3 1 1 6 0 6 10 0 1 3
2023/202425 0 6 4 1 2 4 0 2 0 0 3 3
2024/2025210 0 39 11 19 41 26 7 2 14 13 25 13
2025/20265 5 0 0 0 0 0 0 0 0 0 0 0
Totale 311